A Multicenter, Open-label, Safety Extension Study with Benralizumab (MEDI-563) for Asthmatic Adults on Inhaled Corticosteroid Plus Long-acting β2 Agonist (MELTEMI)
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 07 Feb 2018
At a glance
- Drugs Benralizumab (Primary)
- Indications Asthma
- Focus Adverse reactions; Registrational
- Acronyms MELTEMI
- Sponsors AstraZeneca; AstraZeneca AB
- 07 Aug 2017 Planned End Date changed from 29 Mar 2019 to 6 Mar 2019.
- 07 Aug 2017 Planned primary completion date changed from 29 Mar 2019 to 6 Mar 2019.
- 24 Apr 2017 Status changed from recruiting to active, no longer recruiting.